Pyrazolo [1,5-A] pyrimidine adenosine A2a receptor antagonists

A compound represented by the structural formula I

• or a pharmaceutically acceptable salt thereof, wherein:
• A is alkylene, R16 -arylene, R16-cycloalkylene or R16-heteroaryldiyl;
• X is (O)— or —S(O)2—;
• R1 is alkyl or cycloalkyl;
• R2 is hydrogen, halo or —CN;
• R3 is hydrogen or alkyl;
• R4 is hydrogen,, alkyl, alkoxy, hydroxyalkyl, -allkyl—NR14R15, cycloalkyl, heterocycloalkyl, heterocycloalkyl substituted by alkyl, R8-arylalkyl or R8-heteroarylalkyl;
• or R3 and R4, together with the nitrogen to which they are attached, form a 5-7 membered ring, said ring optionally comprising an additional heteroatom ring member selected from the group consisting of —O—, —S— and —N(R17)—, said ring being optionally substituted by alkyl, hydroxyalkyl, R8-arylalkyl, R8-heteroarylalkyl, —N(R9)—C(O)alkyl, —CO2alkyl, —C(O)NR10OR11 or heterocycloalkyl;
• or R3 and R4, together with the nitrogen to which they are attached, form the group
• R7 is alkyl, R12-phenyl, R12-heteroaryl, cycloalkyl, halo, morpholinyl,
• n is 1 or 2;
• R8 is 1-3 substituents independently selected from the group consisting of hydrogen, alkyl, halo, alkoxy, —CO2H, —CO2-alkyl, —CF3, —CN, —CO2NR14R15, —SO2-alkyl, —SO2NR14R15 and —NR14R15;
• R9 is hydrogen or alkyl;
• R10 and R11 are independently selected from the group consisting of alkyl and cycloalkyl;
• or R10 and R11 form a C4-C5 alkylene chain and together with the nitrogen to which they are attached, form a 5- or 6-membered ring;
• R12 is 1 to 3 substituents independently selected from the group consisting of hydrogen, alkyl, halo, alkoxy, —CO2H, —CO2-alkyl, —CF3, —CN, —CO2NR14R15, —SO2-alkyl, —SO2NR14R15 and —NR14R15;
• R13 is H, OH, hydroxyalkyl or alkyl;
• R14 and R15 are independently selected form the group consisting of hydrogen, alkyl and cycloalkyl;
• R16 is 1 to 3 substituents independently selected from the group consisting of hydrogen, alkyl, halo, OH and alkoxy;
• and
• R17 is hydrogen, alkyl, cycloalkyl or R8-arylalkyl.